HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1762v1 31/4/747    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Lajer, M. Articles by Rossing, P. PubMed PubMed Citation Articles by Lajer, M. Articles by Rossing, P. Social Bookmarking                What's this?

Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy

¹ Steno Diabetes Center, Gentofte, Denmark
² Department of Clinical Chemistry, VU, University Medical Center, Amsterdam, the Netherlands
³ Department of Medical Endocrinology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
⁴ Faculty of Health Science, University of Aarhus, Aarhus, Denmark

Address correspondence and reprint requests to Maria Lajer, Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark. E-mail: mlaj{at}steno.dk

OBJECTIVE—To investigate whether circulating asymmetric dimethylarginine (ADMA) levels are predictive of cardiovascular events, decline in glomerular filtration rate (GFR), end-stage renal disease (ESRD), and all-cause mortality in type 1 diabetic patients.

RESEARCH DESIGN AND METHODS—We performed a prospective observational follow-up study including 397 type 1 diabetic patients with overt diabetic nephropathy (243 men aged 42.1 ± 10.5 years, GFR 76 ± 34 ml/min per 1.73 m²) and a control group of 175 patients with longstanding type 1 diabetes and persistent normoalbuminuria (104 men aged 42.7 ± 9.7 years, duration of diabetes 27.7 ± 8.3 years). Patients were followed for a median 11.3 years (range 0.0–12.9) with yearly measurements of GFR (⁵¹Cr-EDTA plasma clearance) in patients with diabetic nephropathy. Endpoints were fatal and nonfatal cardiovascular disease (CVD), decline in GFR, ESRD, and all-cause mortality.

RESULTS—Among patients with diabetic nephropathy, 37 patients (19.4%) with ADMA levels below the median, compared with 79 patients (43.4%) above the median, suffered a major cardiovascular event during the follow-up period (P < 0.001). This effect persisted after adjustment for conventional CVD risk factors including baseline GFR (adjusted hazard ratio [HR] for elevated ADMA 2.05 [95% CI 1.31–3.20], P = 0.002). Furthermore, elevated ADMA levels predicted an increased rate of decline in GFR, development of ESRD, and all-cause mortality (P < 0.001). After adjustment for well-known progression promoters, including baseline GFR, the HR (adjusted) was 1.85 (95% CI 0.99–3.46, P = 0.055) for ESRD comparing upper and lower median ADMA levels.

CONCLUSIONS—Plasma ADMA levels predict fatal and nonfatal cardiovascular events in patients with type 1 diabetic nephropathy. Furthermore, increased ADMA levels tend to contribute to increased risk of progressive diabetic kidney disease.

Abbreviations: ADMA, asymmetric dimethylarginine • AHT, antihypertensive treatment • CVD, cardiovascular disease • DDAH, dimethylarginine dimethylaminohydrolases • ESRD, end-stage renal disease • GFR, glomerular filtration rate • SDC, Steno Diabetes Center • SDMA, symmetrical dimethylarginine

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?